Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 400

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Open access
Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., Fleseriu, M., van der Lely, A. J., Farrall, A. J., Hermosillo Reséndiz, K., Ruffin, M., Chen, Y., Sheppard, M., on behalf of the Pasireotide C2305 Study Group·2014·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2013-2480
Open this paper in CoChat — free account

Abstract

CONTEXT: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control. OBJECTIVE: Our objective was to demonstrate the superiority of pasireotide LAR over octreotide LAR in medically naive patients with acromegaly. DESIGN AND SETTING: We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries. PATIENTS: A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled. Patients either had previous pituitary surgery but no medical treatment or were de novo with a visible pituitary adenoma on magnetic resonance imaging. INTERVENTIONS: Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months. At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal. MAIN OUTCOME MEASURE: The main outcome measure was the proportion of patients in each treatment arm with biochemical control (GH <2.5 μg/L and normal IGF-1) at month 12. RESULTS: Biochemical control was achieved by significantly more pasireotide LAR patients than octreotide LAR patients (31.3% vs 19.2%; P = .007; 35.8% vs 20.9% when including patients with IGF-1 below the lower normal limit). In pasireotide LAR and octreotide LAR patients, respectively, 38.6% and 23.6% (P = .002) achieved normal IGF-1, and 48.3% and 51.6% achieved GH <2.5 μg/L. 31.0% of pasireotide LAR and 22.2% of octreotide LAR patients who did not achieve biochemical control did not receive the recommended dose increase. Hyperglycemia-related adverse events were more common with pasireotide LAR (57.3% vs 21.7%). CONCLUSIONS: Pasireotide LAR demonstrated superior efficacy over octreotide LAR and is a viable new treatment option for acromegaly.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2013-2480

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 400

Metadata

Authors
Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., Fleseriu, M., van der Lely, A. J., Farrall, A. J., Hermosillo Reséndiz, K., Ruffin, M., Chen, Y., Sheppard, M., & on behalf of the Pasireotide C2305 Study Group
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2014-03-01
Volume
99
Issue
3
Pages
791-799
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2013-2480
OpenAlex
W1996943463
Cited by
400
References
24
FWCI
33.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. https://app.cochat.ai/papers/10.1210/jc.2013-2480
The paper
Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., Fleseriu, M., van der Lely, A. J., Farrall, A. J., Hermosillo Reséndiz, K., Ruffin, M., Chen, Y., Sheppard, M., & on behalf of the Pasireotide C2305 Study Group. (2014). Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2013-2480

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.